HB Wealth Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.06M Buy
19,549
+1,237
+7% +$185K 0.02% 371
2026
Q1
$2.8M Buy
18,312
+950
+5% +$146K 0.02% 357
2025
Q4
$2.39M Buy
17,362
+423
+2% +$55.4K 0.02% 377
2025
Q3
$2.17M Buy
16,939
+3,582
+27% +$437K 0.01% 398
2025
Q2
$1.62M Buy
13,357
+2,064
+18% +$233K 0.01% 420
2025
Q1
$1.26M Buy
11,293
+4,549
+67% +$484K 0.01% 487
2024
Q4
$656K Buy
6,744
+534
+9% +$56.9K 0.01% 534
2024
Q3
$714K Buy
6,210
+516
+9% +$58.5K 0.01% 476
2024
Q2
$606K Hold
5,694
0.01% 483
2024
Q1
$551K Buy
5,694
+1,317
+30% +$135K 0.01% 473
2023
Q4
$442K Sell
4,377
-300
-6% -$29K 0.01% 496
2023
Q3
$476K Buy
4,677
+126
+3% +$12.8K 0.01% 444
2023
Q2
$459K Sell
4,551
-144
-3% -$14.4K 0.01% 438
2023
Q1
$432K Buy
4,695
+650
+16% +$56.8K 0.01% 448
2022
Q4
$367K Buy
4,045
+144
+4% +$12.1K 0.01% 477
2022
Q3
$297K Buy
3,901
+667
+21% +$55.3K 0.01% 439
2022
Q2
$273K Buy
3,234
+202
+7% +$17.7K 0.01% 461
2022
Q1
$266K Buy
+3,032
New +$263K ﹤0.01% 483

Other funds holding NVS

HB Wealth Management's NVS Position: Q2 2026 in Review

HB Wealth Management increased its Novartis (NVS) stake by 6.8% in Q2 2026, buying an estimated $185K and bringing the position to 19,549 shares worth $3.06M. The position accounts for 0.02% of the portfolio, ranked #371.

HB Wealth Management first reported a position in NVS in Q1 2022 and has held it in 18 quarters since. 1,612 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • HB Wealth Management held 19,549 shares of Novartis worth $3.06M as of Q2 2026.
  • HB Wealth Management bought 1,237 Novartis shares in Q2 2026, an estimated $185K.
  • Novartis made up 0.02% of HB Wealth Management's portfolio in Q2 2026, its #371 holding.
  • HB Wealth Management first reported a position in Novartis in Q1 2022 and has held it in 18 quarters since.
  • 1,612 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.